FR2334366A2 - Application a titre d'agents antiviraux de composes d'heteropolyanions contenant du tungstene combine a de l'antimoine - Google Patents

Application a titre d'agents antiviraux de composes d'heteropolyanions contenant du tungstene combine a de l'antimoine

Info

Publication number
FR2334366A2
FR2334366A2 FR7605084A FR7605084A FR2334366A2 FR 2334366 A2 FR2334366 A2 FR 2334366A2 FR 7605084 A FR7605084 A FR 7605084A FR 7605084 A FR7605084 A FR 7605084A FR 2334366 A2 FR2334366 A2 FR 2334366A2
Authority
FR
France
Prior art keywords
ammonium
sodate
tungsto
antimonic
pref
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7605084A
Other languages
English (en)
Other versions
FR2334366B2 (fr
Inventor
Jean-Claude Chermann
Claude Jasmin
Georges Mathe
Marcel Raynaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bpifrance Financement SA
Original Assignee
Agence National de Valorisation de la Recherche ANVAR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agence National de Valorisation de la Recherche ANVAR filed Critical Agence National de Valorisation de la Recherche ANVAR
Priority to GB51415/76A priority Critical patent/GB1573002A/en
Priority to JP14789976A priority patent/JPS5294431A/ja
Publication of FR2334366A2 publication Critical patent/FR2334366A2/fr
Application granted granted Critical
Publication of FR2334366B2 publication Critical patent/FR2334366B2/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G41/00—Compounds of tungsten
    • C01G41/006—Compounds containing tungsten, with or without oxygen or hydrogen, and containing two or more other elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/80—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
    • C01P2002/82—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by IR- or Raman-data
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/60—Optical properties, e.g. expressed in CIELAB-values

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR7605084A 1975-12-10 1976-02-24 Application a titre d'agents antiviraux de composes d'heteropolyanions contenant du tungstene combine a de l'antimoine Granted FR2334366A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB51415/76A GB1573002A (en) 1975-12-10 1976-12-09 Antiviral agent
JP14789976A JPS5294431A (en) 1975-12-10 1976-12-10 Antiivirus agent treatment for virus inffction and prevention method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63941375A 1975-12-10 1975-12-10

Publications (2)

Publication Number Publication Date
FR2334366A2 true FR2334366A2 (fr) 1977-07-08
FR2334366B2 FR2334366B2 (fr) 1982-10-01

Family

ID=24563990

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7605084A Granted FR2334366A2 (fr) 1975-12-10 1976-02-24 Application a titre d'agents antiviraux de composes d'heteropolyanions contenant du tungstene combine a de l'antimoine

Country Status (3)

Country Link
BE (1) BE848836R (fr)
DE (1) DE2655690A1 (fr)
FR (1) FR2334366A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0185584A1 (fr) * 1984-12-03 1986-06-25 Institut Pasteur Utilisation de l'hétéropolyanion (NaSb9W21086)18- pour fabriquer une composition pharmaceutique destinée à être utilisée dans le traitement du sida et des syndromes analogues
FR2587214A1 (fr) * 1985-09-13 1987-03-20 Pasteur Institut Anticoagulants constitues d'heteropolyanions tungstiques et utilisation de ces heteropolyanions a la preparation de medicaments anticoagulants
EP0690722A4 (fr) * 1993-03-18 1997-08-06 Cytimmune Sciences Inc Composition et methode d'abaissement de la toxicite de facteurs biologiquement actifs
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US6528051B2 (en) 1997-11-10 2003-03-04 Cytimmune Sciences, Inc. Methods and compositions for enhancing immune response
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450065A4 (en) * 1988-12-16 1992-01-02 Terumo Kabushiki Kaisha Antiviral agent
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
WO2005065121A2 (fr) 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Procedes et compositions de production d'anticorps monoclonaux
EP2219458B1 (fr) 2007-11-08 2015-07-15 Cytimmune Sciences, Inc. Compositions et procédés de production d'anticorps

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2245374B1 (fr) * 1973-07-27 1977-02-25 Anvar

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0185584A1 (fr) * 1984-12-03 1986-06-25 Institut Pasteur Utilisation de l'hétéropolyanion (NaSb9W21086)18- pour fabriquer une composition pharmaceutique destinée à être utilisée dans le traitement du sida et des syndromes analogues
DE3542165A1 (de) * 1984-12-03 1986-07-10 Centre National De La Recherche Scientifique (C.N.R.S.), Paris Medikament zur behandlung des syndroms der erworbenen immunschwaeche (aids) und entsprechende pharmazeutische zusammensetzungen
FR2587214A1 (fr) * 1985-09-13 1987-03-20 Pasteur Institut Anticoagulants constitues d'heteropolyanions tungstiques et utilisation de ces heteropolyanions a la preparation de medicaments anticoagulants
EP0690722A4 (fr) * 1993-03-18 1997-08-06 Cytimmune Sciences Inc Composition et methode d'abaissement de la toxicite de facteurs biologiquement actifs
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US6528051B2 (en) 1997-11-10 2003-03-04 Cytimmune Sciences, Inc. Methods and compositions for enhancing immune response
US7387900B2 (en) 1997-11-10 2008-06-17 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods

Also Published As

Publication number Publication date
DE2655690A1 (de) 1977-06-23
BE848836R (fr) 1977-05-26
FR2334366B2 (fr) 1982-10-01

Similar Documents

Publication Publication Date Title
ES8700053A1 (es) Procedimiento de obtencion de una composicion para el trata-miento de infecciones virales
FR2334366A2 (fr) Application a titre d'agents antiviraux de composes d'heteropolyanions contenant du tungstene combine a de l'antimoine
ES8405432A1 (es) Procedimiento para la preparacion de polifosfato amonico activado
ES485066A1 (es) Un procedimiento para preparar derivados de piridina o piri-midina
JPS55373A (en) Medicinal compound
GB1528117A (en) Process for the preparation of a hydroxylamine salt and the pretreatment of catalyst compositions used therein
ES394422A1 (es) Procedimiento para la obtencion de derivados de tiopirimi- dina.
GB1427508A (en) Pyrido pyrimidine compounds
ATE3027T1 (de) Verfahren zur hydroxylierung von kuerzerkettigen aliphatischen mono- oder diolefinen.
BG47945A3 (bg) Метод за получаване на органичен цинков комплекс
GB1465042A (en) Catalysts for the manufacture of unsaturated nitriles
SE8802193L (sv) Utvaertes anvaendbar, antiviral farmaceutisk komposition som ackumuleras i huden samt foerfarande foer framsttaellning av densamma
GB967594A (en) 2-(2,6-dimethyl-3-hydroxy-4-tert-butyl-benzyl)-2-imidazoline,and acid addition salts thereof,and process for their manufacture
JPS51136623A (en) Process for preparation of guanidine salts
IT7822979A0 (it) Procedimento di fabbricazione di nitroguanidina da nitrato di guanidina per azione di acido solforico acquoso.
FR2321881A1 (fr) 2,6-diamino-anthraquinones substituees, leur procede de preparation et leurs applications
ES459454A1 (es) Procedimiento para preparar una carga silicea mejorada.
GB1491686A (en) Process for purifying cyanogen chloride
GB1097338A (en) Penicillanyl aldehydes
IT7524350A1 (it) Processo per la preparazione di persolfati di metalli alcalini o di ammonio
GB1492006A (en) Process for the production of maddrell's salt
DE3570675D1 (en) Compounds having cardiotrophic activity, a process for the preparation thereof and pharmaceutical compositions therefrom
ES2005718A6 (es) Un procedimiento para preparar una sal de alcanolamonio o una sal de amonio de un agente tesoactivo.
GB1470747A (en) Pyridazine derivative
ES401174A1 (es) Procedimiento para la preparacion de nuevos esteres alcohi-licos del acido tiolcarbamidico basicamente sustituidos.